A Phase 2 interventional study of Investigational drug and Irinotecan in Colorectal Neoplasms and Diarrhea, sponsored by Celgene Corporation. Terminated at 28 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-01.
Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 200 studies testing irinotecan in Colorectal Neoplasms — 25 open to participants now, 32 under way, 6 of them phase 3. Irinotecan · Colorectal Neoplasms.
Among the 200 studies testing irinotecan in Colorectal Neoplasms, this one is one of 7 that started in 2002, is one of 117 in phase 2, and was the 32nd registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →25 of the 200 studies testing irinotecan in Colorectal Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
Gruppo Oncologico Italia Meridionale · Sites in Italy
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18–80
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–70
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Irinotecan: first FDA approval 1996 (CAMPTOSAR), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
200 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 48 · Phase 2 139 · Phase 3 28 · Phase 4 2
First in 1996; this study’s year is marked. 7 started in 2002.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 47 across the 182 interventional studies. Of the 131 that completed or were terminated, 27 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 200 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene Corporation, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene Corporation is the lead sponsor of 52 studies on the registry; none are open to participants now.
29 studies in Colorectal Neoplasms by Bristol-Myers Squibb: 4 open now, 9 under way, 3 of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, this one is the only one that started in 2002, is one of 5 in phase 2, and was the 1st registered.
Bristol-Myers Squibb’s Colorectal Neoplasms studies by the year they started, since 2002.
7 of the studies testing irinotecan in Colorectal Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03303495Phase 3Sun Yat-sen UniversityA Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | 2026-12-31 |
| NCT06321081Beijing HospitalICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC | 2026-12-30 |
| NCT07229846Yanqiao ZhangA Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | 2027-02 |
| NCT05391126Reema A. PatelGENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care | 2027-05 |
| NCT07570914Tianjin Medical University Cancer Institute and HospitalHepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | 2027-05-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 200 studies testing irinotecan in Colorectal Neoplasms, from their registry updates:
Among Bristol-Myers Squibb’s 29 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
The study will combine a new investigational drug with standard anti-cancer drugs for the treatment of advanced colorectal cancer. The standard and approved treatment for colorectal cancer is to undergo chemotherapy with a combination of irinotecan (also known as CPT-11, Camptosar), 5-fluorouracil (also known as 5-FU), and leucovorin (also known as LV). This is known as the triple therapy. One of the major side effects of CPT-11/5-FU/LV chemotherapy treatment is diarrhea. The purpose of this research study is to see whether adding this investigational drug to the standard treatment for advanced colorectal cancer can reduce the amount of diarrhea a patient experiences. This study will also determine if adding the investigational drug to triple therapy has a positive effect on tumors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study is terminated, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Drugs, Investigational · Irinotecan · Leucovorin